Lund Immunotalks Seminar

We warmly invite you to join us on June 23rd, from 09:00 to 11:00 at Medicon Village, Restaurant Inspira, for an engaging morning focused on clinical immunology – just before your summer plans begin.

We are pleased to welcome two distinguished guest speakers:

• Aurelien Marabelle | Gustave Roussy, Paris – “Cancer Immunotherapy Efficacy rely on Tumor Biology rather than Pathology: Consequences for Personalized Strategies”
• Brian Brown | Mount Sinai, New York – “Immunity is spatial: determinants of response to cancer immunotherapy and mRNA drugs”

Enjoy a networking Fika session sponsored by Miltenyi Biotec in between the talks!

Aurélien Marabelle

Prof. Aurélien Marabelle is a physician-scientist with expertise in oncology (MD) and immunology (PhD). His clinical practice is dedicated to early phase clinical trials of cancer immunotherapies within the Drug Development Department (DITEP) of Gustave Roussy Cancer Center in France. He leads a translational research laboratory (LRTI) with a focus on mechanisms of action of immune targeted therapies. He is also the director of the Clinical Investigation Center BIOTHERIS dedicated to intratumoral immunotherapies. He is a full professor of Clinical Immunology at the University of Paris Saclay. Dr Marabelle was initially trained as a scientist at the Ecole Normale Supérieure de Lyon and King’s College London and as a clinician at the Léon Bérard Cancer Center in Lyon, France. He did his post-doctoral research fellowship in the laboratory of Prof Ronald Levy at Stanford University, CA on strategies to overcome the resistance to immune checkpoint targeted therapies. He has published more than 250 peer-reviewed publications and has a H-index of 60.

Brian Brown

Dr. Brian Brown is the Director of the Icahn Genomics Institute and the Vice Chair of the Department of Immunology at the Mount Sinai Medical Center in New York City. He is an expert in cancer immunology and gene delivery, including both viral and non-viral mediated approaches. He has invented a number of widely used genomics and gene therapy technologies, including microRNA-based targeting, small RNA sequencing adapters, bispecific antibody-targeted nanoparticles, and Perturb-map spatial functional genomics. His lab has identified a number of genes and molecular programs important for the control of tumor microenvironment composition and immunotherapy resistance, and he made important contributions to the understanding of the immune response to gene therapy.